| First Author | Karunarathne K | Year | 2024 |
| Journal | Biomolecules | Volume | 14 |
| Issue | 6 | PubMed ID | 38927020 |
| Mgi Jnum | J:350234 | Mgi Id | MGI:7661374 |
| Doi | 10.3390/biom14060615 | Citation | Karunarathne K, et al. (2024) Crystal Violet Selectively Detects Abeta Oligomers but Not Fibrils In Vitro and in Alzheimer's Disease Brain Tissue. Biomolecules 14(6) |
| abstractText | Deposition of extracellular Amyloid Beta (Abeta) and intracellular tau fibrils in post-mortem brains remains the only way to conclusively confirm cases of Alzheimer's Disease (AD). Substantial evidence, though, implicates small globular oligomers instead of fibrils as relevant biomarkers of, and critical contributors to, the clinical symptoms of AD. Efforts to verify and utilize amyloid oligomers as AD biomarkers in vivo have been limited by the near-exclusive dependence on conformation-selective antibodies for oligomer detection. While antibodies have yielded critical evidence for the role of both Abeta and tau oligomers in AD, they are not suitable for imaging amyloid oligomers in vivo. Therefore, it would be desirable to identify a set of oligomer-selective small molecules for subsequent development into Positron Emission Tomography (PET) probes. Using a kinetics-based screening assay, we confirm that the triarylmethane dye Crystal Violet (CV) is oligomer-selective for Abeta42 oligomers (AbetaOs) grown under near-physiological solution conditions in vitro. In postmortem brains of an AD mouse model and human AD patients, we demonstrate that A11 antibody-positive oligomers but not Thioflavin S (ThioS)-positive fibrils colocalize with CV staining, confirming in vitro results. Therefore, our kinetic screen represents a robust approach for identifying new classes of small molecules as candidates for oligomer-selective dyes (OSDs). Such OSDs, in turn, provide promising starting points for the development of PET probes for pre-mortem imaging of oligomer deposits in humans. |
